NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28.

Article  PubMed  Google Scholar 

Garon EB, Hellmann MD, Carcereny Costa E, Leighl NB, Ahn MJ, Eder JP, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: results from KEYNOTE-001. J Clin Oncol. 2019;37:LBA9015.

Morgensztern D. KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1–49%. J Thorac Dis. 2019;11:S1963–5.

Article  PubMed  PubMed Central  Google Scholar 

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92.

Article  CAS  PubMed  Google Scholar 

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:eaar3593.

Article  PubMed  PubMed Central  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33.

Article  CAS  PubMed  Google Scholar 

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345–62.

Article  CAS  PubMed  Google Scholar 

Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood. 2010;116:1291–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301.

Article  CAS  PubMed  Google Scholar 

Dianat-Moghadam H, Mahari A, Heidarifard M, Parnianfard N, Pourmousavi-Kh L, Rahbarghazi R, et al. NK cells-directed therapies target circulating tumor cells and metastasis. Cancer Lett. 2021;497:41–53.

Article  CAS  PubMed  Google Scholar 

Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol. 2009;182:3530–9.

Article  CAS  PubMed  Google Scholar 

Bryceson YT, Chiang SCC, Darmanin S, Fauriat C, Schlums H, Theorell J, et al. Molecular mechanisms of natural killer cell activation. J Innate Immun. 2011;3:216–26.

Article  CAS  PubMed  Google Scholar 

Katz P, Whalen G, Cupps TR, Ray Mitchell S, Evans M. Natural killer cells can enhance the proliferative responses of B lymphocytes. Cell Immunol. 1989;120:270–6.

Article  CAS  PubMed  Google Scholar 

Carbone E, Ruggiero G, Terrazzano G, Palomba C, Manzo C, Fontana S, et al. A new mechanism of NK cell cytotoxicity activation: the CD40–CD40 ligand interaction. J Exp Med. 1997;185:2053–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blanca IR, Bere EW, Young HA, Ortaldo JR. Human B cell activation by autologous NK cells is regulated by CD40-CD40 ligand interaction: role of memory B cells and CD5 + B cells. J Immunol. 2001;167:6132–9.

Article  CAS  PubMed  Google Scholar 

Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 2017;8:1124.

Article  PubMed  PubMed Central  Google Scholar 

Takanami I, Takeuchi K, Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2001;121:1058–63.

Article  CAS  PubMed  Google Scholar 

Villegas FR, Coca S, Villarrubia VG, Jiménez R, Chillón MJ, Jareño J, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002;35:23–8.

Article  PubMed  Google Scholar 

Backman M, La Fleur L, Kurppa P, Djureinovic D, Elfving H, Brunnström H, et al. Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer. J Pathol. 2021;255:243–56.

Article  CAS  PubMed  Google Scholar 

Hamilton G, Plangger A. The impact of NK cell-based therapeutics for the treatment of lung cancer for biologics: targets and therapy. Biol Targets Ther. 2021;15:265–77.

Article  Google Scholar 

Kim EJ, Cho YH, Kim DH, Ko DH, Do EJ, Kim SY, et al. A phase I/IIa randomized trial evaluating the safety and efficacy of SNK01 plus pembrolizumab in patients with stage IV non-small cell lung cancer. Cancer Res Treat. 2022;54:1005–1016.

Lee SB, Cha J, Kim IK, Yoon JC, Lee HJ, Park SW, et al. A high-throughput assay of NK cell activity in whole blood and its clinical application. Biochem Biophys Res Commun. 2014;445:584–90.

Article  CAS  PubMed  Google Scholar 

Nederby L, Jakobsen A, Hokland M, Hansen TF. Quantification of NK cell activity using whole blood: Methodological aspects of a new test. J Immunol Methods. 2018;458:21–25.

Article  CAS  PubMed  Google Scholar 

Choi SI, Lee SH, Park JY, Kim KA, Lee EJ, Lee SY, et al. Clinical utility of a novel natural killer cell activity assay for diagnosing non-small cell lung cancer: a prospective pilot study. OncoTargets Ther. 2019;ume 12:1661–9.

Article  Google Scholar 

Hansen TF, Nederby L, Zedan AH, Mejlholm I, Henriksen JR, Steffensen KD, et al. Correlation between natural killer cell activity and treatment effect in patients with disseminated cancer. Transl Oncol. 2019;12:968–72.

Article  PubMed  PubMed Central  Google Scholar 

Cho H, Ryu MH, Lee HE, Kim HD, Kang YK. Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine–platinum doublet plus trastuzumab. Cancer Immunol Immunother. 2021. https://link.springer.com/10.1007/s00262-021-03035-x.

Cho YH, Choi MG, Kim DH, Choi YJ, Kim SY, Sung KJ, et al. Natural killer cells as a potential biomarker for predicting immunotherapy efficacy in patients with non-small cell lung cancer. Target Oncol. 2020;15:241–7.

Article  PubMed  Google Scholar 

Choi MG, Kim YJ, Lee JC, Rho JK, Choi C. Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non‐small cell lung cancer. Thorac Cancer. 2020;11:3337–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10:1842–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jakobsen A, Andersen RF, Hansen TF, Jensen LH, Faaborg L, Steffensen KD, et al. Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival. Eur J Cancer. 2021;149:128–33.

Article  CAS  PubMed  Google Scholar 

Raja R, Kuziora M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA, et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res. 2018;24:6212–22.

Article  CAS  PubMed  Google Scholar 

Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res. 2018;24:1872–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell. 2020;183:363–376.e13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wen SWC, Andersen RF, Hansen TF, Nyhus CH, Hager H, Hilberg O, et al. The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2021;10:855–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Calvanese V, Capellera-Garcia S, Ma F, Fares I, Liebscher S, Ng ES, et al. Mapping human haematopoietic stem cells from haemogenic endothelium to birth. Nature. 2022;604:534–40.

留言 (0)

沒有登入
gif